<DOC>
	<DOCNO>NCT00003700</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient untreated acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Untreated Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete response rate toxicity escalate dos daunorubicin patient 60 year old untreated acute lymphoblastic leukemia ( ALL ) . - Determine complete response rate toxicity constant dose daunorubicin patient least 60 year old untreated ALL . - Determine toxicity high dose cytarabine postremission therapy patient . - Determine CNS relapse rate ALL prophylactic intrathecal methotrexate high-dose intravenous chemotherapy replace cranial irradiation . OUTLINE : - Course I : Patients assign 1 2 induction treatment group base age . - Group 1 ( age 60 ) : Patients receive cyclophosphamide IV 15-30 minute day 1 , escalate dos daunorubicin IV 5-10 minute day 1-3 , vincristine IV day 1 , 8 , 15 , 22 , oral prednisone day 1-21 , asparaginase intramuscularly day 5 , 8 , 11 , 15 , 18 , 22 , filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 4 continue least 7 day blood count recover . - Group 2 ( age 60 ) : Patients receive vincristine , asparaginase , cyclophosphamide , G-CSF group 1 , fix dose daunorubicin IV 5-10 minute day 1-3 , oral prednisone day 1-7 . Patients evaluate bone marrow cellularity day 29 . Those M0 , M1 , M2 cellularity proceed course II . Patients M3 cellularity may proceed course II remove study . - Course II ( early intensification ) : Patients receive intrathecal methotrexate cyclophosphamide IV 15-30 minute day 1 , cytarabine IV 3 hour day 1-3 , G-CSF SC begin day 4 . Bone marrow examine day 29 . Patients M0 M1 cellularity course I sign relapse course II proceed course III . Patients M2 M3 cellularity course I must M0 M1 cellularity course II proceed course III . Patients M2 M3 cellularity course II remove study . - Course III : Patients receive intrathecal methotrexate , vincristine IV , methotrexate IV 3 hour day 1 , 8 , 15 oral methotrexate every 6 hour 4 dos begin 6 hour start methotrexate IV day 1 , 2 , 8 , 9 , 15 , 16 . Patients receive leucovorin calcium IV 6 hour last oral methotrexate dose day 2 , 9 , 16 oral leucovorin calcium begin 12 hour leucovorin calcium IV least 4 dos day 3 , 4 , 10 , 11 , 17 , 18 . Patients must leucovorin calcium minimum 3 day begin day 8 15 treatment . Patients maintain M0 M1 cellularity day 29 course III continue therapy . Those M2 M3 cellularity course III remove study . - Course IV ( Late intensification ) : Repeat course I . - Course V ( Late intensification ) : Repeat course II . - Course VI ( CNS intensification ) : Repeat course III . - Course VII ( Prolonged maintenance ) : Patients receive oral mercaptopurine daily , vincristine IV every 4 week , oral prednisone day 1-5 , oral methotrexate day 1 , 8 , 15 , 22 . Courses repeat every 4 week 18 month . Patients testicular disease receive gonadal radiotherapy anytime course I . Chemotherapy halt radiotherapy . Patients follow every 3 month 1 year , every 6 month 2 year , annually 10 year . PROJECTED ACCRUAL : A total 140 patient accrue study within 15 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>1 . Any serious illness would limit survival &lt; 2 year , psychiatric condition would prevent compliance treatment informed consent . 2 . Uncontrolled severe cardiovascular disease . 3 . History pancreatitis overt coagulopathy ( prior cerebrovascular accident hemorrhage , transient ischemic attack deep venous thrombosis ) . 4 . Elevations bilirubin , creatinine , amylase may suggest impaired hepatic , renal , pancreatic function must consider potentially serious obstacle safe tolerance therapy prescribe protocol . 5 . Prior use agent administer protocol nonmalignant disease may reduce likelihood beneficial outcome , also consider prior enrol patient . 6 . Treatment protocol would expose unborn child significant risk . Women men reproductive potential agree use effective mean birth control . 7 . Unequivocal histologic diagnosis Acute Lymphoblastic leukemia ( ALL ) , FAB L1or L2 Acute Undifferentiated Leukemia ( AUL ) . 8 . Age â‰¥ 15 year 9 . Prior Treatment : No prior treatment leukemia , three permissible exception : i. emergency leukapheresis ; ii . emergency treatment hyperleukocytosis hydroxyurea ; iii . cranial RT CNS leukostasis ( one dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>L1 adult acute lymphoblastic leukemia</keyword>
	<keyword>L2 adult acute lymphoblastic leukemia</keyword>
</DOC>